MARKET WIRETradingView • 23h ago
Journey Medical Corporation Estimates – NASDAQ:DERMTradingView report covering Journey Medical Corporation (DERM) market action, institutional positioning, and fundamental catalysts.
Why DERM Stock dropped -7.35% Today — RQD Quant Desk Flash
$4.79 -7.35% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $4.72
Journey Medical Corporation (DERM) carries a Roarable Rating of E (Strong Sell) with 16/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE E • RED ALERT
Cap $145.9M
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER
Click Any Pre-Computed AI Quant Specialist Briefing on DERM Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief)
Is DERM stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼
As of 2026-11-03, Journey Medical Corporation (NASDAQ: DERM) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 16/100 at a spot price of $4.79 (-7.35% 1D, market cap $145.9M). Pillar breakdown: Fundamental Cash Engine 3/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 5/20, FRED Macro Regime Fit 4/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, DERM ranks #1009 in composite RQD confidence.
✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief)
How does DERM compare to NGEN and MENS in the Health Care sector?
▼
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), DERM carries a Roarable E (16/100 RQD), trailing P/E of N/A, gross margin of 65.8%, and ROIC of -19.5%. By comparison, NGEN (NervGen Pharma Corp.) holds a D grade (45/100 RQD, P/E N/A, ROIC —, cap $147.4M) and MENS (Jyong Biotech Ltd.) posts a E grade (33/100 RQD, P/E N/A, ROIC -28.8%, cap $142.9M). Among the 5-stock peer group, DERM leads on earnings multiple (N/A) while DERM leads on capital efficiency (-19.5% ROIC).
✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief)
What are the biggest fundamental strengths and SEC risk factors for DERM?
▼
Per DERM's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001867066), Journey Medical Corporation generated $61.2M in revenue (+11.1% YoY), -$11.4M in net income, and -$12.4M in free cash flow against $94.6M in total assets and $25.3M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.
✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $4.72 (-1.51%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 3/20 (E) • 0% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record Warning: Scores below 50 (16/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-12.7% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →RQD QUANT TACHOMETERRED ALERT • E
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw E · Rk E
Each axis scored 0–20
12M PRICE TARGET CONE-19% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for DERM)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (16/100 Composite)
🔍 WHY DERM SCORES 16/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+5/20 pts (31% of score)
Altman Z-Score 0.74 (DISTRESS RISK (<1.8)) • Piotroski F-Score 5/9
▲ #2 Bullish Driver: Cash Engine Quality+4/20 pts (25% of score)
SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 65.8% Gross Margin
▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)
Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade E$5.91-12.5% Next Q
24
Q2 (-2Q)Grade E$5.17-3.9% Next Q
21
Q3 (-1Q)Grade E$4.97-3.6% Next Q
19
CurrentGrade E$4.79-12.7% Hist 90D α
16
Trajectory: E (24) → E (16)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER
⚔️ Adversarial Opposing Case: What Could Spark a DERM Turnaround Squeeze
While DERM currently carries a cautious 16/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
🚀 Contrarian Squeeze Trigger #1
Established market leader in Health Care with deep daily trading liquidity.
🚀 Contrarian Squeeze Trigger #2
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($6.47) and Max Pain ($5.03) forces dealer call-delta covering toward $10.04.
🚀 Contrarian Squeeze Trigger #3
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
🎲 LIVE PREDICTION MARKET ODDS TIED TO $DERM• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “DERM Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why DERM Stock dropped -7.35% Today — RQD Quant Desk Flash
Journey Medical Corporation (DERM) dropped -7.35% to $4.79, trading at 9% of its 52-week range ($4.31 – $9.56). Stretched risk/reward at current multiples (-20% return on capital) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 9% of its 52-week range ($4.31 – $9.56) with RSI-14 at 40.5 (NEUTRAL RANGE).
- ▸Volatility Profile: Historical 20-day realized swing band of ±12.5% around $4.79 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable E (Strong Sell) backed by 65.8% gross margin and $0 annual free cash flow.
Live DERM Headlines & Catalysts
MARKET WIREStock Titan • 1d ago
An investment adviser reports passive ownership of 2.45M shares in Journey Medical (DERM).Stock Titan report covering Journey Medical Corporation (DERM) market action, institutional positioning, and fundamental catalysts.
MARKET WIREMarketBeat • 1d ago
Journey Medical (NASDAQ:DERM) Stock Moved Down to "Hold" by Wall Street ZenMarketBeat report covering Journey Medical Corporation (DERM) market action, institutional positioning, and fundamental catalysts.
CATALYSTYahoo Finance • 1d ago
Korro Bio, Inc. (KRRO) Surges 29.7%: Is This an Indication of Further Gains?Yahoo Finance report covering Journey Medical Corporation (DERM) market action, institutional positioning, and fundamental catalysts.
CATALYSThttps://www.siam.in/ • 1d ago
Journey Medical Corporation (DERM) Jumps 6.04% as Shares Reclaim Ground Toward $5.09 - Fair Value Gaphttps://www.siam.in/ report covering Journey Medical Corporation (DERM) market action, institutional positioning, and fundamental catalysts.
MARKET WIREMarketBeat • 1d ago
Journey Medical's (DERM) Buy Rating Reiterated at HC WainwrightMarketBeat report covering Journey Medical Corporation (DERM) market action, institutional positioning, and fundamental catalysts.
MARKET WIREYahoo! Finance Canada • 1d ago
Medexus Pharmaceuticals Inc. (MDP.TO) Seasonal Returns Chart - Yahoo FinanceYahoo! Finance Canada report covering Journey Medical Corporation (DERM) market action, institutional positioning, and fundamental catalysts.
MARKET WIREMarketBeat • 1d ago
Journey Medical Q3 2026 Earnings Date and EstimatesMarketBeat report covering Journey Medical Corporation (DERM) market action, institutional positioning, and fundamental catalysts.
MARKET WIREBenzinga • 8d ago
HC Wainwright & Co. Reiterates Buy on Journey Medical, Maintains $13 Price TargetHC Wainwright & Co. analyst Brandon Folkes reiterates Journey Medical (NASDAQ:DERM) with a Buy and maintains $13 price target.
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring DERM)
- ✓Walkthrough of DERM's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
DERM // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -6.45%🛡️ HOLDING TREND SUPPORT
2026-11-03O $5.41H $5.41L $4.79C $4.79VOL 235.1K
RES: $9.12SUP: $4.56SMA50: $6.47SMA200: $6.63
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
DERM Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth
vs. +11.1% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger
No active Ellis Vennor swing setup published on DERM today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for DERM. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for DERM today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (DERM)
Health Care Rank #1009 of 1015
⚔️ NGEN vs DERM Full Matrix →
1. Head-to-Head Health Care Peer Comparison (DERM vs. NGEN, MENS, MSLE, RNA)
Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)Across 1015 tracked Health Care securities in the Roarable RQD universe, Journey Medical Corporation (DERM) ranks #1009 by composite RQD confidence (16/100, grade E) and #608 by equity capitalization ($145.9M). Within this direct 5-issuer industry benchmark cohort, DERM leads on earnings valuation at N/A trailing P/E, while DERM leads on capital efficiency and profitability with -19.5% ROIC and 65.8% gross margin. MSLE currently holds the highest overall quantitative score in the immediate peer group at 46/100 (D) compared with DERM at 16/100 (E).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| DERM
ACTIVE
Journey Medical Corporation | E | 16/100 | — | 65.8% | -19.5% | -7.35% | $145.9M | Benchmark Subject |
| NGEN NervGen Pharma Corp. | D | 45/100 | — | — | — | -1.46% | $147.4M | /ngen-vs-derm → |
| MENS Jyong Biotech Ltd. | E | 33/100 | — | — | -28.8% | -0.53% | $142.9M | /mens-vs-derm → |
| MSLE Satellos Bioscience Inc. | D | 46/100 | — | — | — | -4.48% | $142.2M | /msle-vs-derm → |
| RNA Atrium Therapeutics Inc. | D | 44/100 | — | — | — | +3.39% | $141.5M | /rna-vs-derm → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001867066 ↗In its most recent audited fiscal period (FY2025, filed 2025-12-31), Journey Medical Corporation (DERM) reported GAAP revenue of $61.2M (+11.1% vs. FY2024 revenue of $55.1M , and +2.6% cumulative change since FY2023) , GAAP net income of -$11.4M, operating cash flow of -$12.4M, and free cash flow of -$12.4M (-36.3% YoY). On the balance sheet, DERM closed FY2025 with $94.6M in total assets against $25.3M in total debt (Altman Z-Score: 0.74, Piotroski F-Score: 5/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $61.2M | -$11.4M | -$12.4M | -$12.4M | $94.6M | $25.3M |
| FY2024 (FY) | 2024-12-31 | $55.1M | -$14.7M | -$9.1M | -$9.1M | $80.2M | $24.9M |
| FY2023 (FY) | 2023-12-31 | $59.7M | -$3.9M | $5.2M | $5.2M | — | — |
3. DERM Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs DERM stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-03, Journey Medical Corporation (NASDAQ: DERM) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 16/100 at a spot price of $4.79 (-7.35% 1D, market cap $145.9M). Pillar breakdown: Fundamental Cash Engine 3/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 5/20, FRED Macro Regime Fit 4/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, DERM ranks #1009 in composite RQD confidence.
How does DERM compare to NGEN and MENS in the Health Care sector?
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), DERM carries a Roarable E (16/100 RQD), trailing P/E of N/A, gross margin of 65.8%, and ROIC of -19.5%. By comparison, NGEN (NervGen Pharma Corp.) holds a D grade (45/100 RQD, P/E N/A, ROIC —, cap $147.4M) and MENS (Jyong Biotech Ltd.) posts a E grade (33/100 RQD, P/E N/A, ROIC -28.8%, cap $142.9M). Among the 5-stock peer group, DERM leads on earnings multiple (N/A) while DERM leads on capital efficiency (-19.5% ROIC).
What are the biggest fundamental strengths and SEC risk factors for DERM?
Per DERM's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001867066), Journey Medical Corporation generated $61.2M in revenue (+11.1% YoY), -$11.4M in net income, and -$12.4M in free cash flow against $94.6M in total assets and $25.3M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.
Where is DERM trading relative to its 50-day, 200-day, and 52-week technical levels?
DERM last traded at $4.79 (-7.35% on volume of 142,618 shares), positioning the stock -25.97% below its 50-day simple moving average ($6.47) and -27.75% below its 200-day simple moving average ($6.63). Across its 52-week range of $4.31 to $9.56, DERM sits at the 9.1% percentile with a 14-day RSI of 40.5 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($4.19 to $5.39).
ROARABLE RATING BRIEF • RQD 16/100 (E)
✓ SEC XBRL & RQD VERIFIED
DERM — Journey Medical Corporation: What the Facts Mean to a Prospective Investor
Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31
1. Roarable Rating Brief: What This Means to a Prospective Investor
Journey Medical Corporation (DERM) earns a live Roarable RQD composite score of 16/100, corresponding to a E letter grade (Roarable Strong Sell) at a spot price of $4.79 (-7.35% 1D, market capitalization $145.9M).
- Fundamental Cash Engine (3/20): Anchored by return on invested capital (ROIC) of -19.5%, gross margin of 65.8%, operating margin of -13.3%, and free cash flow yield of -8.15%.
- Whale 13F & Options Flow (3/20) + Insider Conviction (3/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
- Macro Regime Fit (4/20) + Forensic Balance Sheet (5/20): Incorporates a 1.00x equity beta, Altman Z-Score of 0.74, Piotroski F-Score of 5/9, and Debt/Equity of 0.79x.
2. Business Model, Unit Margins & SEC Financial Trajectory
Journey Medical Corporation is a NASDAQ-listed issuer classified in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry. Its market capitalization is $0.2B.
In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Journey Medical Corporation (DERM) reported $61.2M in annual revenue (up from $55.1M in FY2024, +11.1% YoY) and -$11.4M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($59.7M revenue, -$3.9M net income) through FY2025, DERM scaled operating cash flow to -$12.4M and free cash flow to -$12.4M, backed by $94.6M in total assets against $25.3M in total debt.
3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff
- 🐂 Primary Bull Case (E • RQD 16/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of -8.15% and institutional whale pillar of 3/20. With Fundamental Cash Engine at 3/20 and Institutional Whale Flow at 3/20, sustained execution supports upside toward the upper end of the $4.31 – $9.56 52-week range.
- 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against -13.3% operating margins and a 1.00x macro beta.
4. 2nd-Order Butterfly Ripples & Key Questions to Watch
Upstream and downstream dependency mapping is therefore — Sector correlation data beyond the Beta of 1.0 is — A prospective investor should watch for any future disclosure of supplier, distributor, or licensing dependencies, since none are currently mapped.
- Key Question #1: Can DERM sustain or expand its -13.3% operating margin and -19.5% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
- Key Question #2: Following FY2025 revenue of $61.2M and free cash flow of -$12.4M, how will capital allocation balance growth reinvestment against $25.3M in total debt?
- Key Question #3: How sensitive is DERM's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?
DERM Live News Feed, Press Releases & Catalyst Wire
Real-time company headlines, analyst actions, and sector developments for Journey Medical Corporation (DERM) • Click "Debate This Headline" to argue it in the Roar Pit below
🟡 MARKET WIRE TradingView • 23h ago
Journey Medical Corporation Estimates – NASDAQ:DERM TradingView report covering Journey Medical Corporation (DERM) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Stock Titan • 1d ago
An investment adviser reports passive ownership of 2.45M shares in Journey Medical (DERM). Stock Titan report covering Journey Medical Corporation (DERM) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE MarketBeat • 1d ago
Journey Medical (NASDAQ:DERM) Stock Moved Down to "Hold" by Wall Street Zen MarketBeat report covering Journey Medical Corporation (DERM) market action, institutional positioning, and fundamental catalysts.
🟢 CATALYST Yahoo Finance • 1d ago
Korro Bio, Inc. (KRRO) Surges 29.7%: Is This an Indication of Further Gains? Yahoo Finance report covering Journey Medical Corporation (DERM) market action, institutional positioning, and fundamental catalysts.
🟢 CATALYST https://www.siam.in/ • 1d ago
Journey Medical Corporation (DERM) Jumps 6.04% as Shares Reclaim Ground Toward $5.09 - Fair Value Gap https://www.siam.in/ report covering Journey Medical Corporation (DERM) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE MarketBeat • 1d ago
Journey Medical's (DERM) Buy Rating Reiterated at HC Wainwright MarketBeat report covering Journey Medical Corporation (DERM) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Yahoo! Finance Canada • 1d ago
Medexus Pharmaceuticals Inc. (MDP.TO) Seasonal Returns Chart - Yahoo Finance Yahoo! Finance Canada report covering Journey Medical Corporation (DERM) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE MarketBeat • 1d ago
Journey Medical Q3 2026 Earnings Date and Estimates MarketBeat report covering Journey Medical Corporation (DERM) market action, institutional positioning, and fundamental catalysts.
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE
3 Active Posts & Replies
DERM Bull vs. Bear Conversation Board — What's Your Call at $4.79?
🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON DERM 🐻 33% BEARISH CONVICTION
MA MacroHawk_NYC RQD DEBATE OPENER • Cross-Asset Macro Desk 🐂 BULLISH
🎯 Target: $6.26 (+21.1%)
📌 Pinned Debate Whale 13F flow scores 12/20, suggesting institutional accumulation is more constructive than the fundamentals alone imply.
Whale 13F flow scores 12/20, suggesting institutional accumulation is more constructive than the fundamentals alone imply.. When you look under the hood at DERM, Fundamental Cash Engine is 1/20 with 65.8% gross margins and -19.5% ROIC. Bears are staring in the rearview mirror while institutional 13F flow (3/20) has been quietly accumulating below $9.56. My 12M target is $6.26.
EarningsSniper 🐂 BULL
@RiskArb_Desk Shorting a 3/20 institutional whale-flow stock at $5.17 is dangerous when funds are rotating into Health Care.
RI RiskArb_Desk RQD DEBATE OPENER • Hedged Event Driven 🐻 BEARISH
🎯 Target: $3.93 (-24.0%)
Spot @ $5.17 ROIC of -19.5%, FCF yield of -8.15%, and an Altman Z of 0.74 point to a cash engine and balance sheet under forensic stress.
Fading this rally in DERM at $5.17. ROIC of -19.5%, FCF yield of -8.15%, and an Altman Z of 0.74 point to a cash engine and balance sheet under forensic stress.. With a beta of 1.0 and the stock sitting at $5.17 (52-wk range $4.31–$9.56), the easy multiple expansion is already priced in.